See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Nintendo
Donald Trump
Natural Disasters
Baseball
Republican Party
Social Media
US Politics
European Union
Democratic Party
Taxes
Senate
Published • loading... • Updated

First Patient Dosed in Trial of KINE-101 for CIDP

Summary by Rare Disease Advisor
The first patient in a new phase 1b/2a clinical trial to investigate KINE-101 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) has been dosed, according to a press release from the treatment’s developer, Kine Sciences. The new trial is a dose escalation trial and will investigate increasing doses of KINE-101 in Korean patients with CIDP who have already received at least 1 frontline therapy. Read more about CIDP expe…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Rare Disease AdvisorRare Disease Advisor

First Patient Dosed in Trial of KINE-101 for CIDP

The first patient in a new phase 1b/2a clinical trial to investigate KINE-101 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) has been dosed, according to a press release from the treatment’s developer, Kine Sciences. The new trial is a dose escalation trial and will investigate increasing doses of KINE-101 in Korean patients with CIDP who have already received at least 1 frontline therapy. Read more about CIDP expe…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Rare Disease Advisor broke the news in on Friday, September 20, 2024.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

South Korea

South Korea

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal